Cover Image
close this bookUNAIDS-Sponsored Regional Workshops to Discuss Ethical Issues in Preventive HIV Vaccine Trials (UNAIDS, 2000, 52 p.)
close this folderWORKSHOP REPORTS
close this folderBANGKOK, THAILAND, 20-22 APRIL, 1998
View the document1. Collaboration in Phase I, II and III Trials
View the document2. Community
View the document3. Ethical and Scientific Review
View the document4. Intellectual Property
View the document5. Control Arm in Trials
View the document6. Informed Consent
View the document7. Gender, Pregnancy and Breast-Feeding
View the document8. Children
View the document9. Protection from Discrimination
View the document10. Vaccine-Induced HIV-Seropositivity
View the document11. Counselling
View the document12. Post-Exposure Prophylaxis (PEP)
View the document13. Treatment and Care
View the document14. Compensation
View the document15. Availability of Vaccine

8. Children


Children and adolescents should not be enrolled in preventive HIV vaccine trials.


It was suggested that adult data might be extrapolated to adolescents following completion of a trial. In addition, children and adolescents could be enrolled in later trials after efficacy has been shown in adults.

The age cut-off for eligibility was discussed briefly. It was noted that in some countries the age of legal majority is as low as 12, and that this may not be appropriate for enrolling participants. The definition of ‘child’ in the International Covenant on the Rights of the Child is under 18 years of age, and this was suggested as an appropriate age for vaccine trials.